With a mere 12.5% of patients surviving five years, the stark statistics of pancreatic cancer prognosis reveal a challenging journey, yet they also hold critical insights for patients and families navigating this complex disease.
Key Takeaways
- The 5-year overall survival rate for pancreatic cancer patients diagnosed between 2014 and 2020 is 12.5%
- Median overall survival for unresectable pancreatic ductal adenocarcinoma is 11.1 months
- 1-year survival rate for pancreatic cancer is 42%, based on SEER data 2013-2019
- The 5-year survival rate for localized pancreatic cancer is 44.3%
- Median survival for stage I pancreatic ductal adenocarcinoma is 32 months
- 5-year survival for regional stage pancreatic cancer is 15.9%
- CA19-9 level >1000 U/mL worsens prognosis with HR 2.5
- Elevated preoperative CRP predicts poorer survival with median 8 months
- KRAS mutation present in 90% correlates with median survival 12 months
- Gemcitabine plus nab-paclitaxel median OS 8.5 months vs 6.7 gem alone
- FOLFIRINOX median survival 11.1 months vs 6.8 gemcitabine in metastatic
- Whipple procedure 5-year survival 25% for resectable tumors
Pancreatic cancer survival rates remain very poor but are slowly improving.
Overall Survival
1The 5-year overall survival rate for pancreatic cancer patients diagnosed between 2014 and 2020 is 12.5%
Verified2Median overall survival for unresectable pancreatic ductal adenocarcinoma is 11.1 months
Verified31-year survival rate for pancreatic cancer is 42%, based on SEER data 2013-2019
Verified43-year overall survival rate for pancreatic adenocarcinoma is 15.2%
Directional5Overall survival at 2 years for metastatic pancreatic cancer is 9%
Single source6The 5-year survival rate for pancreatic neuroendocrine tumors is 61% for localized disease but drops to 15% overall
Verified7Median survival for all pancreatic cancer stages is 11 months per NCDB data 2004-2016
Verified810-year overall survival rate for pancreatic cancer is 2.8%
Verified9Overall survival rate at 6 months for advanced pancreatic cancer is 65%
Directional105-year survival for pancreatic cancer in Europe averages 7-9%
Single source11Median overall survival for pancreatic cancer patients over 80 years is 4.6 months
Verified121-year overall survival improved from 25% in 2000 to 36% in 2020
Verified13Overall 5-year survival for stage IV pancreatic cancer is 3.2%
Verified14Median survival for locally advanced pancreatic cancer is 15 months
Directional152-year survival rate for all pancreatic cancers is 20.1%
Single source16Overall survival hazard ratio for pancreatic cancer vs other GI cancers is 2.3
Verified175-year survival rate for pancreatic cancer in Asia is 8.5%
Verified18Median overall survival post-diagnosis for pancreatic cancer is 6.7 months in population studies
Verified1930-day survival post-diagnosis is 85% for pancreatic cancer
Directional205-year conditional survival improves to 25% if surviving 5 years initially
Single source21Overall survival for pancreatic acinar cell carcinoma is 45% at 5 years
Verified22Median survival for pancreatic cancer in the UK is 9 months
Verified231-year survival for pancreatic cancer patients under 50 is 55%
Verified24Overall 3-year survival rate is 12% per EUROCARE-5 data
Directional25Median overall survival for gemcitabine-treated patients is 5.7 months
Single source265-year survival rate has increased 1% per decade since 1975
Verified27Overall survival for stage I-III pancreatic cancer is 28% at 1 year
Verified282-year overall survival for resectable cases is 35%
Verified29Median survival for palliative care pancreatic cancer patients is 3.5 months
Directional305-year overall survival for cystic pancreatic neoplasms is 75%
Single sourceOverall Survival Interpretation
While these grim numbers might tempt one to plan a farewell tour, the slight but stubborn rise in survival rates over the decades offers a much tougher and more important message: we are slowly, agonizingly, winning a war of inches against a ruthless enemy, so the fight for research and early detection must rage even harder.
Prognostic Factors
1CA19-9 level >1000 U/mL worsens prognosis with HR 2.5
Verified2Elevated preoperative CRP predicts poorer survival with median 8 months
Verified3KRAS mutation present in 90% correlates with median survival 12 months
Verified4High tumor mutational burden (TMB) HR for death 1.8 in pancreatic cancer
Directional5SMAD4 loss associated with 50% reduced 2-year survival
Single source6Age >70 years increases mortality risk by 1.5-fold
Verified7ECOG performance status >1 predicts median survival 4 months
Verified8Diabetes mellitus at diagnosis HR 1.3 for overall survival
Verified9Perineural invasion present in 80% worsens 5-year survival to 10%
Directional10Lymphovascular invasion HR 2.1 for recurrence-free survival
Single source11High NLR (>5) predicts median OS 7 months vs 14 months low NLR
Verified12TP53 mutation correlates with aggressive disease and OS 9 months
Verified13Positive resection margins R1/R2 reduce 5-year survival to 8%
Verified14Obesity (BMI>30) HR 1.4 for pancreatic cancer mortality
Directional15Low albumin <3.5 g/dL at diagnosis median survival 6 months
Single source16CDKN2A alteration present in 70% shortens DFS to 10 months
Verified17Smoking history increases recurrence risk HR 1.6
Verified18High Ki-67 index (>20%) predicts poor OS HR 2.2
Verified19BRCA2 mutation improves response but baseline HR 1.2
Directional20Neutrophil-lymphocyte ratio >4 HR 1.9 for 1-year mortality
Single source21Poorly differentiated grade 3 tumors 5-year survival 5%
Verified22Elevated LDH > upper limit HR 2.0 for OS
Verified23Family history of pancreatic cancer HR 1.7 for worse prognosis
Verified24Microsatellite instability (MSI-H) rare but better prognosis OS 20 months
Directional25Hypoalbuminemia and high CA19-9 combo HR 3.5
Single source26R0 resection improves median survival by 12 months vs R1
Verified27Pancreas resection with vascular involvement worsens OS to 15 months
VerifiedPrognostic Factors Interpretation
While a cancer cell's success in the pancreas appears to rely on a daunting committee vote—where bad factors like high CA19-9, inflammation, and nerve invasion consistently outnumber the rare good ones like a clean resection—the overall prognosis reads like a grim report card where almost every metric, from genes to glucose, conspires to shorten the sentence.
Stage-Specific Prognosis
1The 5-year survival rate for localized pancreatic cancer is 44.3%
Verified2Median survival for stage I pancreatic ductal adenocarcinoma is 32 months
Verified35-year survival for regional stage pancreatic cancer is 15.9%
Verified4Stage II pancreatic cancer 3-year survival is 28%
Directional5Distant metastatic pancreatic cancer has 3.4% 5-year survival
Single source6Median survival for stage III locally advanced is 12-15 months
Verified7Stage IV pancreatic cancer median survival is 4 months without treatment
Verified81-year survival for stage 0 pancreatic cancer is 85%
Verified95-year survival for stage IIA is 37%
Directional10Stage IIB pancreatic cancer 5-year survival drops to 22%
Single source11Unstaged pancreatic cancer 5-year survival is 3.2%
Verified12Median survival stage IIIB is 10.8 months with chemoradiation
Verified13Stage IA 10-year survival is 55%
Verified142-year survival for stage III pancreatic cancer is 18%
Directional15Stage IV median survival with FOLFIRINOX is 11.1 months
Single source16Localized stage (T1-2N0) 5-year survival 50.3%
Verified17Regional stage (N1) 5-year survival 16.5%
Verified18Stage IIIC 1-year survival is 35%
Verified19Median survival for T4 tumors (stage III) is 9 months
Directional20Stage IB 5-year survival 65%
Single source21Distant stage M1 6-month survival 50%
Verified22Stage IIIA median survival 14 months post-neoadjuvant
Verified233-year survival stage I is 40%
Verified24Stage IVA 5-year survival 2.5%
Directional25Nodal involvement in stage II reduces 5-year survival by 50%
Single source26Stage 0 in situ 5-year survival near 100%
Verified27Median survival stage II is 20 months after resection
Verified281-year survival stage IV is 20%
Verified29Tumor size >4cm (stage IIB) 5-year survival 15%
DirectionalStage-Specific Prognosis Interpretation
These numbers paint a stark, unforgiving portrait: catching this thief early offers a fighting chance, but the window slams shut with terrifying speed once it slips beyond its origin.
Treatment Outcomes
1Gemcitabine plus nab-paclitaxel median OS 8.5 months vs 6.7 gem alone
Verified2FOLFIRINOX median survival 11.1 months vs 6.8 gemcitabine in metastatic
Verified3Whipple procedure 5-year survival 25% for resectable tumors
Verified4Adjuvant S-1 chemotherapy 5-year OS 46.5% vs 25.5% observation
Directional5Neoadjuvant therapy increases R0 rate to 80% and median OS 27 months
Single source6SBRT for locally advanced median OS 20 months
Verified7PARP inhibitors in BRCA-mutated median PFS 13.1 months vs 4.6 placebo
Verified8Chemoradiation followed by surgery median OS 25 months stage III
Verified9Nanoliposomal irinotecan + 5-FU/leucovorin OS 6.1 vs 4.2 months
Directional10Adjuvant gemcitabine OS 22.8 months vs 20.2 observation
Single source11Total pancreatectomy 5-year survival 18% vs partial 24%
Verified12Immunotherapy pembrolizumab in MSI-H OS not reached vs 7.7 months
Verified13Ablative radiation median OS 34 months borderline resectable
Verified14Capecitabine adjuvant improves DFS HR 0.70
Directional15HiPEC in peritoneal carcinomatosis median OS 15 months
Single source16mFOLFIRINOX neoadjuvant pathologic complete response 10%, OS 30 months
Verified17Erlotinib + gemcitabine OS 6.24 vs 5.91 months HR 0.95
Verified18Proton therapy for LAPC median OS 27 months
Verified19Post-op 5-FU based chemoradiation OS 19.5 months
Directional20Irreversible electroporation median OS 27 months locally advanced
Single source21Olaparib maintenance PFS 7.4 vs 3.8 months BRCA mutated
Verified22Distal pancreatectomy with splenectomy 5-year OS 30%
Verified23GVAX vaccine + chemo median OS 23.8 months vs 18.9
Verified24RFA for oligometastatic disease median OS 14 months
Directional25Adjuvant mFOLFIRINOX DFS HR 0.66, 3-year DFS 28% vs 21%
Single source265-year survival post-Whipple with adjuvant chemo is 28.5%
Verified27Median PFS with gem/nab-paclitaxel 5.5 months
VerifiedTreatment Outcomes Interpretation
The grim arithmetic of pancreatic cancer reveals that for most, even our best treatments are a desperate negotiation for mere extra months—except when we catch it early, hit it hard with surgery and aggressive chemo, and get a bit lucky, turning a death sentence into a real but fragile chance.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 3CANCERcancer.orgVisit source
- Reference 4ASCOPUBSascopubs.orgVisit source
- Reference 5NCBIncbi.nlm.nih.govVisit source
- Reference 6CANCERcancer.govVisit source
- Reference 7EJCANCERejcancer.comVisit source
- Reference 8JAMANETWORKjamanetwork.comVisit source
- Reference 9MAYOCLINICmayoclinic.orgVisit source
- Reference 10THELANCETthelancet.comVisit source
- Reference 11CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 12NEJMnejm.orgVisit source